Kymera Therapeutics (NASDAQ:KYMR) COO Sells $27,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) COO Jeremy Chadwick sold 300 shares of Kymera Therapeutics stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $90.00, for a total transaction of $27,000.00. Following the transaction, the chief operating officer directly owned 61,202 shares of the company’s stock, valued at approximately $5,508,180. This represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Kymera Therapeutics Stock Performance

KYMR stock opened at $84.91 on Monday. The stock has a market cap of $6.93 billion, a PE ratio of -23.07 and a beta of 2.28. Kymera Therapeutics, Inc. has a 12 month low of $28.06 and a 12 month high of $103.00. The company has a 50-day moving average price of $84.63 and a 200 day moving average price of $75.76.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The company had revenue of $2.87 million during the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. Kymera Therapeutics’s quarterly revenue was down 60.8% on a year-over-year basis. During the same period last year, the firm earned ($0.88) earnings per share. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -3.65 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently modified their holdings of the business. Keudell Morrison Wealth Management lifted its position in shares of Kymera Therapeutics by 5.9% in the 1st quarter. Keudell Morrison Wealth Management now owns 6,990 shares of the company’s stock worth $582,000 after purchasing an additional 390 shares during the period. Rockefeller Capital Management L.P. lifted its position in shares of Kymera Therapeutics by 21,538.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 25,533 shares of the company’s stock worth $1,987,000 after purchasing an additional 25,415 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $198,000. Virtu Financial LLC purchased a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $2,123,000. Finally, T. Rowe Price Investment Management Inc. lifted its position in shares of Kymera Therapeutics by 3.0% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 629,745 shares of the company’s stock worth $49,001,000 after purchasing an additional 18,524 shares during the period.

Analyst Ratings Changes

Several equities research analysts have issued reports on KYMR shares. Piper Sandler boosted their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. UBS Group boosted their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research report on Tuesday, March 3rd. Citigroup boosted their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Jefferies Financial Group started coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.90.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: FDA granted Fast Track designation to KT‑621 (oral STAT6 degrader) for eosinophilic asthma — accelerates development pathway and can increase regulatory interaction and potential commercial value if clinical data remain positive. FDA Fast Track for KT-621
• Positive Sentiment: Strong analyst and institutional support — multiple recent buy/outperform ratings and a median analyst target near $120, plus large institutional additions reported in recent quarters, provide a bullish backdrop for longer-term upside. Quiver / Analyst & Institutional Snapshot
• Neutral Sentiment: Company will report Q1 2026 results and host a webcast on April 30 — an upcoming earnings call adds near‑term event risk and potential for volatility depending on guidance, cash burn and clinical spend details. Q1 2026 Results Announcement
• Neutral Sentiment: Short interest data reported appears to be a data anomaly (shows 0 shares / NaN change) — not meaningful for positioning until corrected by exchanges/data providers.
• Negative Sentiment: Recent insider sales: COO Jeremy Chadwick sold 300 shares (~$90 each) and Director Bruce Booth executed sales (including a 5,900‑share reduction) — while some trades were under pre‑arranged 10b5‑1 plans, continued insider selling can pressure sentiment. Chadwick Insider Sale Booth Form 4 (10b5-1)
• Negative Sentiment: Broad pattern of insider selling over the past 6 months (many executive sales and relatively few purchases) increases perception of near‑term distribution risk despite institutional buying. Quiver Insider Trading Summary

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.